- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03787472
Clinical Evaluation of Manufacturing Processes for a Reusable Multifocal Optical Design in a Presbyopic Population
Clinical Evaluation of Manufacturing Curing Processes for a Reusable Multifocal Optical Design in a Presbyopic Population
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Florida
-
Maitland, Florida, Forenede Stater, 32751
- Maitland Vision Center
-
-
Missouri
-
Raytown, Missouri, Forenede Stater, 64133
- Advanced Eyecare
-
-
New York
-
Jamestown, New York, Forenede Stater, 14701
- Spectrum Eyecare
-
-
Ohio
-
Beachwood, Ohio, Forenede Stater, 44122
- Western Reserve Vision Care, Inc
-
Granville, Ohio, Forenede Stater, 43023
- Procare Vision Centers
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Potential subjects must satisfy all the following criteria to be enrolled in the study:
- The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
- The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
- The subject must be at least 40 years of age and not greater than 70 years of age.
- The subject's distance spherical equivalent refraction must be in the range of +1.25 D to +3.75 D in each eye.
- The subject's refractive cylinder must be ≤0.75 D in each eye.
- The subject's ADD power must be in the range of +0.75 D to +2.50 D.
- The subject must have distance best corrected visual acuity of 20/20-3 or better in each eye.
- Subjects must own a wearable pair of spectacles if required for their distance vision.
- The subject must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration).
The subject must either already be wearing a presbyopic contact lens correction (e.g., reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.) or if not respond positively to at least one symptom on the "Presbyopic Symptoms Questionnaire".
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- Currently pregnant or lactating.
- Any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.
- Any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g. hepatitis, tuberculosis).
- Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.
- Entropion, ectropion, extrusions, chalazia, recurrent styes, dry eye, glaucoma, history of recurrent corneal erosions.
- Any previous, or planned, ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, lid procedures, dacryocystorhinostomy cataract surgery, retinal surgery, etc.).
- A history of amblyopia, strabismus or binocular vision abnormality.
- Any current ocular infection or inflammation.
- Any current ocular abnormality that may interfere with contact lens wear.
- Use of any of the following oral medications within 1 week prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, topical scopolamine, systemic steroids.
- Use of any ocular medication, with the exception of rewetting drops.
- History of herpetic keratitis.
- Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
- Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
- Any known hypersensitivity or allergic reaction to Optifree®Replenish® multipurpose care solution, sodium fluorescein or Eye-Cept® rewetting drop solution.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Test/Control
Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into one the sequence (Test/Control).
|
CONTROL
TEST
|
|
Eksperimentel: Control/Test
Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into the sequence (Control/Test).
|
CONTROL
TEST
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
CLUE Vision
Tidsramme: 2-ugers opfølgning
|
Det overordnede syn blev vurderet ved hjælp af Contact Lens User Experience™ (CLUE) spørgeskemaet.
CLUE er et valideret patientrapporteret udfaldsspørgeskema (PRO) til at vurdere patientoplevelsesegenskaber for bløde kontaktlinser (komfort, syn, håndtering og indpakning) i en kontaktlinsebærende befolkning i USA i alderen 18-65.
Afledte CLUE-scores ved hjælp af Item Response Theory (IRT) følger en normalfordeling med en befolkningsgennemsnitsscore på 60 (SD 20), hvor højere score indikerer en mere gunstig/positiv respons med et interval på 0-120.
|
2-ugers opfølgning
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
logMAR Visual Acuity
Tidsramme: 2-Week Follow-up
|
Binocular visual performance on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated under high luminance and high contrast conditions at three distances: Distance (3 meters) was measured using ETDRS (Early Treatment Diabetic Retinopathy Study) charts; Intermediate (64 centimeters) and Near (40 centimeters) were measured using Reduced Guillon-Poling Charts. Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20. |
2-Week Follow-up
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- CR-6317
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Synsstyrke
-
VisiblyAfsluttetDigital Acuity produktForenede Stater
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityAfsluttetVisual Health of Virtual RealityKina
-
University of Illinois at Urbana-ChampaignAfsluttetKognitiv forandring | Behandling, Visual SpatialForenede Stater
-
University of Illinois at Urbana-ChampaignAfsluttetKognitiv forandring | Arbejdshukommelse | Hæmning (psykologi) | Behandling, Visual SpatialForenede Stater
-
New York City Health and Hospitals CorporationAfsluttetGrøn stær | Nethindesygdom | Visual Pathway DisorderForenede Stater
-
Neuro-Eye Diagnostic Systems, LLCNeuro-ophthalmology of Texas PLLCTilmelding efter invitationMakula sygdom | Visual Pathway Disorder | SynsnervesygdomForenede Stater
-
University of ZurichBalgrist University HospitalRekruttering
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeGliom af lav grad | Tilbagevendende Visual Pathway Gliom | Refractory Visual Pathway Gliom | Tilbagevendende pilocytisk astrocytom i barndommen | Tilbagevendende neurofibromatose type 1 | Refraktær neurofibromatose type 1Forenede Stater
-
Cairo UniversityRekrutteringVisual til at sammenligne det visuelle resultat mellem AcrySof™ IQ Vivity™ og TECNIS Synergy™ intraokulær linse (model ZFR00V)Egypten
Kliniske forsøg med JJV Investigational senofilcon A Multifocal Lens1
-
Johnson & Johnson Vision Care, Inc.AfsluttetSynsstyrkeForenede Stater
-
Johnson & Johnson Vision Care, Inc.AfsluttetSynsstyrkeForenede Stater
-
Johnson & Johnson Vision Care, Inc.Afsluttet
-
Johnson & Johnson Vision Care, Inc.AfsluttetSynsstyrkeForenede Stater
-
Johnson & Johnson Vision Care, Inc.AfsluttetSynsstyrkeForenede Stater
-
Johnson & Johnson Vision Care, Inc.AfsluttetKlinisk evaluering af et genanvendeligt multifokalt optisk design i en presbyopisk befolkningsfase 2SynsstyrkeForenede Stater
-
Brien Holden VisionAfsluttetBrydningsfejl | PresbyopiAustralien
-
Alcon ResearchAfsluttetPresbyopiForenede Stater